The Scientist - Home

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

Actual cases may be as much as 6 to 24 times higher than reported, but we’re still a long way off from herd immunity.

If confirmed, the result means people migrated to North America much earlier than thought, but some experts remain unconvinced.

Researchers try unprecedented data sharing and cooperation to understand COVID-19—and develop a model for diseases beyond the coronavirus pandemic.

Upon seeing pregnant women sick with COVID-19 at a University of Pennsylvania hospital, researchers there wrote trial protocols for blood transfusions to treat the disease that include expecting mothers.

These antiviral proteins are produced by the body as a natural defense against viral infections and synthetic interferons might help prevent or treat the beginning stages of SARS-CoV-2 infection.

A handful of viruses have been associated with long-term, debilitating symptoms in a subset of those who become infected. Early signs hint that SARS-CoV-2 may do the same.

Reports of the infection—including one death this month—recently shook up social media. But, unlike COVID-19, plague is a disease that countries have more or less got under control.

The intersection between water, air, and insects’ intricately decorated surfaces turn out to be the key to explain why droplets bounce so quickly off of them.

Intelligence officials from the US, UK, and Canada point the finger at Cozy Bear, a group with links to the Russian government.

Researchers demonstrate that the SARS-CoV-2 spike protein is more stable and binds the human ACE2 receptor with much higher affinity than the spike protein of its closest known relative, bat coronavirus RaTG13.

The presence of a particular set of RNAs in the blood forewarns of an onset of severe symptoms and points to the cells involved.